88 FR 45 pg. 14370 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-PS23-002, Enhancing Telehealth Strategies To Support Retention and Adherence to Antiretroviral Therapy (ART) and RFA-PS23-005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-Traditional Settings: Emergency Department; Amended Notice of Closed Meeting
Type: NOTICEVolume: 88Number: 45Page: 14370
Page: 14370FR document: [FR Doc. 2023-04698 Filed 3-7-23; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Centers for Disease Control and Prevention
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-RFA-PS23-002, Enhancing Telehealth Strategies To Support Retention and Adherence to Antiretroviral Therapy (ART) and RFA-PS23-005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-Traditional Settings: Emergency Department; Amended Notice of Closed Meeting
Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)- RFA-PS23-002, Enhancing Telehealth Strategies to Support Retention and Adherence to Antiretroviral Therapy (ART) and RFA-PS23-005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department, May 24-25, 2023, 10 a.m.-5 p.m., EDT, Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329, in the original FRN. The meeting was published in the Federal Register on February 13, 2023, Volume 88, Number 29, page/s/ 9290.
The meeting is being amended to remove RFA-PS23-005, Expanding Rapid Initiation of Antiretroviral Therapy in Non-traditional Settings: Emergency Department and replace with RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected and the date the teleconference is has changed and should read as follows:
Date: May 11-12, 2023.
Time: 10 a.m.-5 p.m. (EDT).
Place: Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.
The meeting is closed to the public.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, Telephone: (404) 718-8833; Email: GAnderson@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-04698 Filed 3-7-23; 8:45 am]
BILLING CODE 4163-18-P